Cargando…

Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia

BACKGROUND: The comparative effectiveness of antipsychotic long-acting injections (LAIs) and oral medication is not clear due to various methodological problems. METHODS: To compare the effectiveness of LAIs and oral antipsychotics in preventing readmission in patients with schizophrenia, we perform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hye Ok, Seo, Gi Hyeon, Lee, Boung Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958777/ https://www.ncbi.nlm.nih.gov/pubmed/31956334 http://dx.doi.org/10.1186/s12991-019-0254-2

Ejemplares similares

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium
por: Lambert, Tim, et al.
Publicado: (2011)

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval
por: Gharabawi, Georges M, et al.
Publicado: (2007)

Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis
por: Correll, Christoph U., et al.
Publicado: (2017)

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
por: Alphs, Larry, et al.
Publicado: (2011)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting
por: Barlati, Stefano, et al.
Publicado: (2022)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey
por: Keenan, Alexander, et al.
Publicado: (2022)

Employment status of patients with schizophrenia spectrum disorder treated with long acting injectable paliperidone palmitate: Real world mirror image study
por: Markovic, M.
Publicado: (2022)

Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
por: Markowitz, Michael, et al.
Publicado: (2013)

Real-world treatment patterns for patients 80 years and older with early lung cancer: a nationwide claims study
por: Lee, Kyungjong, et al.
Publicado: (2018)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

The Impact of Long-acting Paliperidone in Reducing Hospitalizations and Clinical Severity in Recent Onset Schizophrenia: A Mirror-image Study in Real-world Clinical Setting
por: Peitl, Vjekoslav, et al.
Publicado: (2022)

Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan
por: Iwata, Nakao, et al.
Publicado: (2020)

Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
por: Gutiérrez‐Rojas, Luis, et al.
Publicado: (2022)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Risk of Breast Cancer in Association with the Use of Second-generation Antipsychotics
por: Joo, Sung Woo, et al.
Publicado: (2022)

Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia
por: Kim, Sung-Wan, et al.
Publicado: (2023)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study
por: Roussidis, Andreas, et al.
Publicado: (2013)

Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience
por: Zhang, Tingting, et al.
Publicado: (2021)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study
por: Zheng, Shuo-Han, et al.
Publicado: (2022)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louzã, Mário Rodrigues, et al.
Publicado: (2011)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
por: Singh, Dhiren, et al.
Publicado: (2009)

Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
por: Catalán, Rosa, et al.
Publicado: (2011)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso, Claudio, et al.
Publicado: (2017)

Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”
por: James, Suneeta, et al.
Publicado: (2019)

The place of Long Acting Injectables (LAI) in the treatment of Schizophrenia: Current perspectives
Publicado: (2022)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records
por: Meyer, Jonathan M., et al.
Publicado: (2017)

Application of artificial intelligence in a real-world research for predicting the risk of liver metastasis in T1 colorectal cancer
por: Han, Tenghui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_akh2rv5lgs0at8koi3fqk6rq3t